Suppr超能文献

选择性抑制Src 家族激酶 SU6656 通过促进骨形成与骨吸收解偶联增加小鼠骨量。

Selective inhibition of Src family kinases by SU6656 increases bone mass by uncoupling bone formation from resorption in mice.

机构信息

Service of Bone Diseases, Department of Internal Medicine Specialties, University Hospital of Geneva, 1205 Geneva, Switzerland.

Service of Bone Diseases, Department of Internal Medicine Specialties, University Hospital of Geneva, 1205 Geneva, Switzerland.

出版信息

Bone. 2018 Aug;113:95-104. doi: 10.1016/j.bone.2018.05.006. Epub 2018 May 8.

Abstract

Mice deficient in the non-receptor tyrosine kinase Src exhibit high bone mass due to impaired bone resorption and increased bone formation. Although several Src family kinase inhibitors inhibit bone resorption in vivo, they display variable effects on bone formation. SU6656 is a selective Src family kinase inhibitor with weaker activity towards the non-receptor tyrosine kinase Abl and receptor tyrosine kinases which are required for appropriate osteoblast proliferation, differentiation and function. Therefore, we sought to determine whether SU6656 could increase bone mass by inhibiting bone resorption and by stimulating bone formation, and to explore its mechanisms of action. Four-month-old female C57Bl/6J mice received intraperitoneal injections of either 25 mg/kg SU6656 or its vehicle every other day for 12 weeks. SU6656-treated mice exhibited increased bone mineral density, cortical thickness, cancellous bone volume and trabecular thickness. SU6656 inhibited bone resorption in mice as shown by reduced osteoclast number, and diminished expressions of Oscar, Trap5b and CtsK. SU6656 did not affect Rankl or Opg expressions. However, it blocked c-fms signaling, osteoclastogenesis and matrix resorption, and induced osteoclast apoptosis in vitro. In addition, SU6656 stimulated bone formation rates at trabecular, endosteal and periosteal bone envelopes, and increased osteoblast number in trabecular bone. SU6656 did not affect expressions of clastokines favoring bone formation in mice. However, it stimulated osteoblast differentiation and matrix mineralization by specifically facilitating BMP-SMAD signaling pathway in vitro. Knockdown of Src and Yes mimicked the stimulatory effect of SU6656 on osteoblast differentiation. In conclusion, SU6656 uncouples bone formation from resorption by inhibiting osteoclast development, function and survival, and by enhancing BMP-mediated osteoblast differentiation.

摘要

Src 非受体酪氨酸激酶缺陷的小鼠由于骨吸收受损和骨形成增加而表现出高骨量。虽然几种 Src 家族激酶抑制剂在体内抑制骨吸收,但它们对骨形成的影响不同。SU6656 是一种选择性 Src 家族激酶抑制剂,对非受体酪氨酸激酶 Abl 和受体酪氨酸激酶的活性较弱,而这些激酶对于适当的成骨细胞增殖、分化和功能是必需的。因此,我们试图确定 SU6656 是否可以通过抑制骨吸收和刺激骨形成来增加骨量,并探讨其作用机制。四个月大的雌性 C57Bl/6J 小鼠每隔一天接受 25mg/kg 的 SU6656 或其载体的腹腔注射,共 12 周。SU6656 处理的小鼠表现出骨密度、皮质厚度、松质骨体积和小梁厚度增加。SU6656 抑制了小鼠的骨吸收,表现为破骨细胞数量减少,Oscar、Trap5b 和 CtsK 的表达减少。SU6656 不影响 Rankl 或 Opg 的表达。然而,它阻断了 c-fms 信号转导、破骨细胞发生和基质吸收,并在体外诱导破骨细胞凋亡。此外,SU6656 刺激了小梁、内骨和骨膜骨形成率,并增加了小梁骨中成骨细胞的数量。SU6656 不影响促进骨形成的 clastokines 在小鼠中的表达。然而,它通过体外特异性促进 BMP-SMAD 信号通路,刺激成骨细胞分化和基质矿化。Src 和 Yes 的敲低模拟了 SU6656 对成骨细胞分化的刺激作用。总之,SU6656 通过抑制破骨细胞的发育、功能和存活,并通过增强 BMP 介导的成骨细胞分化,将骨形成与骨吸收解偶联。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验